by MARTHA ROSENBERG Illinois (Where Our Governors Make Our License Plates)
Revelations of Wyeth's pay-to-play, ghost-written articles in medical journals made public by Sen. Charles Grassley's (R- Iowa) this week could not come at a worse time for the company. The hormone-maker's bellwether case, Wyeth vs. Levine, is before the Supreme Court testing whether approval of a drug by a federal agency pre-empts the right of injured consumers to sue. Wyeth was outed as spending $801,000 in just three months this year lobbying Congress, the White House, the FDA, and the Justice Department against the "generic menace." And its signature product line, the hormone drugs Prempro and Premarin, still kill.